Últimas noticias sobre Sunrise New Energy (NASDAQ:EPOW) Bolsa

Sunrise New Energy

Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is into the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.

Pre-Market Outlook

Markets

Movers

ACON

AEON

BCTX

CPHC

EKSO

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

KITT

LDTC

MBOT

MEGL

MNSO

NSTS

SPPL

WFCF

Explora los mayores movimientos en el premercado con ganancias superiores al 100% y pérdidas significativas antes de la apertura.

Acciones de Smart Share Global se disparan un 44%; 20 acciones que se mueven en el premercado

Sunrise New Energy Co., Ltd - Class A Ordinary Shares

Sunrise New Energy Co Ltd

Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)&nbsp;is making a significant move in the AI sector with a $300 million investment in&nbsp;DDN, a company known for its expertise in data storage and analysis. 
What Happened: The investment represents the first external funding for DDN, valuing the Chatsworth, California-based firm&nbsp;at $5 billion. Founded in&nbsp;1998 by computer scientists Alex&nbsp;Bouzari and Paul Bloch, DDN&nbsp;provides computing equipment and software essential for managing data during AI model training and deployment,&nbsp;The Wall Street Journal <a href="https://www.wsj.com/tech/ai/blackstone-to-make-300-million-investment-in-ai-data-company-03f9c4aa">reported</a>&nbsp;on Thursday.
Initially serving&nbsp;government agencies and research organizations,&nbsp;DDN has shifted its focus as businesses increasingly adopt AI technologies. CEO Bouzari stated that Blackstone&#8217;s investment will help expand DDN&#8217;s business-customer base, making AI more cost-effective.
DDN&#8217;s technology is integral to major AI infrastructure projects, including the Colossus supercomputer by Elon Musk&#8216;s xAI. The company is considered a strong competitor in the field and could potentially pursue an IPO in the coming years, sources suggest.
Blackstone&#8217;s investment strategy aligns with its broader AI focus, having previously acquired data-center operator QTS and engaged in significant deals with Digital Realty and AirTrunk. The firm has also supported CoreWeave in financing rounds backed by AI chips.
Why It Matters: The investment by Blackstone comes at a time when major tech companies are heavily investing in AI infrastructure. Recently, Microsoft Corp. announced plans to <a href="https://www.benzinga.com/25/01/42801720/microsoft-to-invest-80-billion-in-ai-data-centers-for-fiscal-2025">allocate $80 billion </a>toward AI data centers for fiscal 2025. This move underscores the growing demand for computing power necessary for AI model training and deployment.
Furthermore, Blackstone&#8217;s strategic investments in <a href="https://www.benzinga.com/25/01/42801720/microsoft-to-invest-80-billion-in-ai-data-centers-for-fiscal-2025">AI-related companies</a>, such as its acquisition of a stake in Citrin Cooperman Advisors LLC, highlight its commitment to expanding its presence in the AI sector. These investments are part of a broader trend among private equity firms to fuel growth in technology and advisory services.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42890464/softbank-owned-arm-eyes-acquisition-of-oracle-backed-chip-designer-ampere-computing-amid-nvidias-dominance-report">SoftBank-Owned Arm Eyes Acquisition Of Oracle-Backed Chip Designer Ampere Computing Amid Nvidia&#8217;s Dominance: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

News

General

MSFT

Blackstone Invests $300 Million In AI Data Firm That Powers Elon Musk's xAI Supercomputer

A &#8220;supermajority&#8221; of workers at BlueOval SK battery plant in Kentucky has filed a petition with the National Labor Relations Board (NLRB) for a vote to form their union with the United Auto Workers (UAW), the union said on Wednesday.
What Happened: The petition was filed on Tuesday, UAW said, without clarifying the percentage of workers who supported it. BlueOval SK is a joint venture of Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and South Korea&#8217;s SK On.
In November, a <a href="https://www.benzinga.com/24/11/42104199/supermajority-of-workers-at-fords-jv-battery-plant-sign-union-authorization-cards-says-uaw">majority of workers at&nbsp;BlueOval SK signed cards</a> showcasing their support for UAW. However, the company hired anti-union consultants in a bid to stop the workers from organizing, UAW said. 
While companies can voluntarily recognize workers once a majority sign cards supporting unionization, in case they don&#8217;t, there is an election overseen by NLRB where workers must vote in the majority to form a union.
Why It Matters:&nbsp;In September, workers at Ultium's battery plant in Spring Hill, Tennessee&nbsp;<a href="https://www.benzinga.com/news/24/09/40724845/gm-lg-ultium-cells-jv-agrees-to-union-recognition-at-tennessee-battery-plant-says-uaw" target="_blank" rel="noreferrer noopener">formed their union</a>. Ultium is a joint venture between General Motors and LG Energy Solution that makes batteries for the former's electric vehicles.
Workers at BlueOval SK held a town hall with UAW members from Ultium Cells in December to discuss the perks of organizing, the UAW said. 
Last year, UAW pledged<a href="https://www.benzinga.com/news/24/02/37255447/can-40m-secure-unionization-from-tesla-to-toyota-uaw-pledges-big-to-help-non-union-auto-workers-orga" target="_blank" rel="noreferrer noopener">&nbsp;$40 million to support the organizing efforts&nbsp;</a>of non-union autoworkers and battery workers in the U.S. under the banner of major manufacturers such as&nbsp;Mercedes-Benz Group,&nbsp;Tesla Inc,&nbsp;and&nbsp;Toyota&nbsp;Motor Corp, among others.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42891397/non-foundation-series-cheaper-cybertrucks-join-tesla-inventory">Tesla&#8217;s Inventory Now Includes Non-Foundation Series Cybertrucks</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Workers At Ford JV In Kentucky Petition NLRB For Vote To Form Union

<h3>Companies Reporting Before The Bell</h3>
<h3>Companies Reporting After The Bell</h3>
• Accolade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) is likely to report quarterly loss at $0.16 per share on revenue of $105.99 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ACCD

Earnings Scheduled For January 9, 2025

Multiple bets tied to the ongoing fire disaster in Los Angeles have surfaced on cryptocurrency-based prediction platform Polymarket, raising ethical concerns about such money-making opportunities.
What Happened: More than 30,000 people had to evacuate the Pacific Palisades neighborhood of Los Angeles as a catastrophic wildfire raged, endangering life and property.
In response, as many as 8 separate betting contracts came up on Polymarket, a Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POL</a>)-based forecasting market that allows users to use cryptocurrencies to predict the outcome of events and make money.
One notable betting <a href="https://polymarket.com/event/will-the-palisades-fire-be-contained-by-friday">question</a> on the platform was, &#8220;Will&nbsp;the Palisades fire be contained&nbsp;by Friday?&#8221; on which about $87,000 has already been wagered. Bettors saw just a 2% possibility of this happening.
Another <a href="https://polymarket.com/event/will-palisades-fire-spread-to-santa-monica-by-sunday?tid=1736406268506">bet </a>was titled, &#8220;Will Palisades wildfire spread to Santa Monica by Sunday?&#8221; About 66% odds were in favor as of this writing.
These gambles sparked strong reactions from the public. Jacob R. Adkins, an X user, asked, &#8220;It says a lot about a society when we've resorted to entertaining ourselves by betting on how much worse a natural disaster could get.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It says a lot about a society when we've resorted to entertaining ourselves by betting on how much worse a natural disaster could get.
&mdash; Jacob R. Adkins (@JacobRAdkins3) <a href="https://twitter.com/JacobRAdkins3/status/1877056992998555711?ref_src=twsrc%5Etfw">January 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another user, going by the pseudonym corp_liberation, called the betting &#8220;immoral.&#8221;
&#8220;Why do you even have such a line?? These are people&#8217;s homes and lives. This is NOT a game!&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Betting on the spread of a fire is immoral. Why do you even have such a line?? These are people&#39;s homes and lives. This is NOT a game!
&mdash; corp_liberation (@corp_liberation) <a href="https://twitter.com/corp_liberation/status/1877135639860121700?ref_src=twsrc%5Etfw">January 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42890745/us-government-granted-permission-to-liquidate-65-billion-in-bitcoin-seized-from-silk-road-case-report">US Government Silk Road Bitcoin Holdings Drop To 0 Amid Report DOJ Approved To Sell $6.5 Billion Worth Of Crypto</a>
Polymarket has attached a disclaimer for all its wildfire-related bets, stating that the idea was to provide factual, real-time news to those impacted by the calamity.
Note that Polymarket is not available to<a href="https://www.benzinga.com/24/11/41838037/will-polymarket-return-to-the-us-after-getting-trump-victory-right-ceo-says-its-part-of-the-plan" target="_blank" rel="noreferrer noopener"> U.S. residents </a>due to regulatory hurdles. The federally regulated prediction platform Kalshi didn&#8217;t have any such <a href="https://kalshi.com/markets/kxfema/states-that-declare-natural-disasters">bets </a>as yet.
Bettors <a href="https://polymarket.com/event/when-will-the-palisades-fire-be-fully-contained?tid=1736409008879" target="_blank" rel="noreferrer noopener">saw </a>a 65% possibility of the calamity getting fully contained by Jan. 31, according to the odds for the contract titled, "When will the Palisades wildfire be fully contained?""
Why It Matters: This isn&#8217;t the first time Polymarket has been in the spotlight for its betting markets on sensitive issues. 
Last year, the platform faced criticism for facilitating bets on the Israel-Hezbollah conflict. 
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)&nbsp;co-founder Vitalik Buterin defended Polymarket, highlighting its role in <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41110897/ethereum-creator-vitalik-buterin-bats-for-polymarkets-model-amid-concerns-over-betting-on-">providing accurate information and preventing misinformation</a>. 
It&#8217;s worth noting that Buterin has skin in the game, having participated in Polymarket&#8217;s $70 million funding round in May of last year.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/42890191/trump-themed-nfts-launch-on-bitcoin-network-for-first-timeheres-what-you-should-know">Trump-Themed NFTs Debut On Bitcoin Network — One Card Gets Listed At $1.9 Million</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Representative Image. Photo Courtesy: Wikimedia

$ETH

$POL

Los Angeles Wildfires Will Be Tamed By This Day, Predict Polymarket Users — Observers Raise Ethical Question

The Tender Offer is for the outstanding notes listed in the table below (collectively, the "Notes" and each a "Series" of Notes), in the order of priority shown in the table below, and subject to the 2027 Notes Tender Cap set forth in the table below.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Title of Security</td>
<td colspan="1" rowspan="1">CUSIP(1)</td>
<td colspan="1" rowspan="1">Issuer</td>
<td colspan="1" rowspan="1">Aggregate Principal Amount Outstanding</td>
<td colspan="1" rowspan="1">2027 Notes Tender Cap(2) (in millions)</td>
<td colspan="1" rowspan="1">Acceptance Priority Level(3)</td>
<td colspan="1" rowspan="1">Reference U.S. Treasury Security</td>
<td colspan="1" rowspan="1">Early Tender Premium(4)</td>
<td colspan="1" rowspan="1">Fixed spread (basis points)</td>
<td colspan="1" rowspan="1">Bloomberg Reference Page(5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
6.375% Senior Notes due 2027
(the "2027 Notes")&#x2A;
</td>
<td colspan="1" rowspan="1">
403949 AK6
U4322C AD5
403949 AP5
</td>
<td colspan="1" rowspan="1">HF Sinclair</td>
<td colspan="1" rowspan="1">$399,875,000</td>
<td colspan="1" rowspan="1">$150,000,000</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">2.625% U.S.T. due 4/15/25</td>
<td colspan="1" rowspan="1">$30.00</td>
<td colspan="1" rowspan="1">50 bps</td>
<td colspan="1" rowspan="1">FIT3</td>
</tr>
<tr>
<td colspan="1" rowspan="1">5.875% Senior Notes due 2026&#x2A;</td>
<td colspan="1" rowspan="1">
403949 AF7
U4322C AB9
403949 AB6
</td>
<td colspan="1" rowspan="1">HF Sinclair</td>
<td colspan="1" rowspan="1">$797,100,000</td>
<td colspan="1" rowspan="1">N/A.</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">4.250% U.S.T. due 12/31/25</td>
<td colspan="1" rowspan="1">$30.00</td>
<td colspan="1" rowspan="1">50 bps</td>
<td colspan="1" rowspan="1">FIT4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">5.875% Senior Notes due 2026&#x2A;</td>
<td colspan="1" rowspan="1">436106AA6</td>
<td colspan="1" rowspan="1">HollyFrontier</td>
<td colspan="1" rowspan="1">$202,900,000</td>
<td colspan="1" rowspan="1">N/A.</td>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1">4.250% U.S.T. due 12/31/25</td>
<td colspan="1" rowspan="1">$30.00</td>
<td colspan="1" rowspan="1">50 bps</td>
<td colspan="1" rowspan="1">FIT4</td>
</tr>
</tbody>
</table>
</figure>

DINO

Reported Earlier, HF Sinclair Upsizes Cash Tender Offer To $1.05B For Outstanding Debt Securities

NYMT

Reported Earlier, New York Mortgage Trust Prices $75M 9.125% Senior Notes Due 2030 With Nasdaq Listing Planned

Recent Highlights &amp; Accomplishments
<ul>
<li>Generated preliminary unaudited fourth quarter revenue of approximately&nbsp;$8.3 million, and preliminary unaudited full year 2024 total revenue of approximately&nbsp;$22.5 million</li>
<li>Received FDA approval for Eversense&#xAE; 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia.</li>
<li>Patient base increased 56% in 2024 over 2023 to approximately 6,000 global patients</li>
<li>Reached a milestone of over a 1,000 annual U.S. Eversense prescribers during 2024</li>
<li>Continued strong interest in Eversense 365, as evidenced by the following early U.S. launch performance indicators:
<ul>
<li>Direct to Consumer (DTC) leads have doubled in Q4 compared to the pre-launch third quarter</li>
<li>New patient shipments of approximately 600 in December were the highest monthly total in the Company's history</li>
<li>The number of patients switching to Eversense from competitive CGM's has increased 49% since Eversense 365 launch</li>
<li>118% increase in patient referrals from physicians since launch</li>
</ul>
</li>
<li>Following recent appreciation in Company's share price, determined not to proceed with previously announced Special Meeting of stockholders to consider reverse stock split.</li>
</ul>
 &nbsp;

SENS

Reported Earlier, Senseonics Reports $22.5M Preliminary 2024 Revenue With $8.4M In Q4, 56% YoY Patient Growth, And Milestone Eversense 365 Launch Success

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) Chief Technology Officer Shyam Sankar highlighted the limitations of automation in enterprise artificial intelligence, as the data analytics firm faces renewed scrutiny over its soaring valuation and recent institutional selling.
What Happened: &#8220;If all of the value is in automation, what have we been doing for the last 20 years with self-driving cars? We&#8217;ve been handling edge cases,&#8221; Sankar stated, emphasizing that automation&#8217;s effectiveness is constrained by exceptional scenarios that require human oversight.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">"[With LLMs], the value is in automation, and in enterprise autonomy. Maybe you can be 50% more productive with a copilot, but [unlocking] all of the economic value requires thinking about AI as a type of labor." Watch Palantir CTO <a href="https://twitter.com/ssankar?ref_src=twsrc%5Etfw">@ssankar</a> explain why the most powerful… <a href="https://t.co/57bShrdI6v">pic.twitter.com/57bShrdI6v</a>
&mdash; Palantir (@PalantirTech) <a href="https://twitter.com/PalantirTech/status/1876991053842055327?ref_src=twsrc%5Etfw">January 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The comments come as Cathie Wood&#8216;s ARK Invest sold 196,728 PLTR <a href="https://www.benzinga.com/trading-ideas/technicals/25/01/42843542/palantir-stock-the-ark-is-rocking-as-palantirs-rally-hits-resistance">shares worth approximately</a> $15 million across its flagship funds, including ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>). 
The sale follows Morgan Stanley&#8216;s recent &#8220;underweight&#8221; rating and $60 price target, despite the stock&#8217;s remarkable 355% surge over the past year.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/42890496/cybertruck-was-my-hero-today-says-ross-gerber-after-teslas-truck-allowed-him-to-navigate-california-wildfires-in-safety">&#8216;Cybertruck Was My Hero Today,&#8217; Says Ross Gerber After Tesla&#8217;s Truck Allowed Him To Navigate California Wildfires In Safety</a>
Why It Matters: The institutional selling presents a stark contrast to CNBC host Jim Cramer&#8216;s bullish stance, who recently indicated interest in adding <a href="https://www.benzinga.com/markets/equities/25/01/42806417/jim-cramer-works-sunday-brainstorm-on-buying-palantir-and-tesla-stock-calls-them-protective-intellectual-blankets">PLTR to his portfolio</a>. The stock has attracted increased <a href="https://www.benzinga.com/news/global/24/12/42331892/trump-eyes-shyam-sankar-for-pentagon-role-while-palantir-gains-from-border-crisis-contracts-analyst-says-this-is-a-win-for-the-stock">attention amid reports</a> that Sankar is being considered for a top Pentagon research position.
Wedbush Securities Managing Director Dan Ives identifies Palantir as a leader in <a href="https://www.benzinga.com/news/global/24/12/42331892/trump-eyes-shyam-sankar-for-pentagon-role-while-palantir-gains-from-border-crisis-contracts-analyst-says-this-is-a-win-for-the-stock">enterprise AI transformation</a>, though government revenue growth slowed to 10% in 2023 from over 20% in 2022.
Trading at a reported 80% premium compared to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42811388/palantir-trades-in-the-red-during-monday-premarket-as-morgan-stanley-assigns-underw">high-growth software peers</a>, PLTR closed at $68.23 on Wednesday, with <a href="https://www.benzinga.com/quote/PLTR/analyst-ratings">analyst price targets</a> ranging widely from UBS&#8217;s $80 to Wolfe Research&#8217;s $7.50, reflecting the market&#8217;s divided outlook on the company&#8217;s valuation.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42890464/softbank-owned-arm-eyes-acquisition-of-oracle-backed-chip-designer-ampere-computing-amid-nvidias-dominance-report">SoftBank-Owned Arm Eyes Acquisition Of Oracle-Backed Chip Designer Ampere Computing Amid Nvidia&#8217;s Dominance: Report</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

ARKK

ARKW

PLTR

Palantir CTO Shyam Sankar Challenges Automation's Potential As Selling Pressure Mounts: 'What Have We Been Doing For 20 Years?'

Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) slipped by 25.63% in after-hours on Wednesday after it missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% on an annual basis.
What Happened: The preliminary earnings results for the fourth quarter pegged a 150% increase in net product revenue to $50 million, as compared to $19.5 million in the fourth quarter of 2023. This missed the consensus analyst estimate by 5.12%, which was <a href="https://www.benzinga.com/quote/AVDL/earnings">expected </a>to be $52.7 million, according to <a href="https://www.benzinga.com/quote/AVDL/earnings">Benzinga</a>.
The biopharmaceutical company is focused on treating cataplexy, excessive daytime sleepiness, and other sleep disorders in adults and children above seven.
The company reported a full-year net product revenue of approximately $169 million compared to $28 million in 2023. Its cash flow from operations stood at approximately $73 million for the quarter ended Dec. 31, 2024.
Greg Divis, CEO of Avadel Pharmaceuticals, highlighted 2024 as a pivotal year, emphasizing the consistent patient adoption of LUMRYZ and the overwhelmingly positive feedback from both patients and providers regarding the life-changing benefits of its once-nightly dosing regimen.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/01/42871340/regional-banks-can-thrive-despite-big-bank-dominance-truist-securities-highlights-three-key-paths-for-thriving-regional-banks">Regional Banks Can Thrive Despite Big Bank Dominance: Truist Securities Highlights Three Key Paths For Thriving Regional Banks</a>
Why It Matters: There was a 275% increase from 900 patients on LUMRYZ in 2023 to 2,500 in 2024. According to its press release, demand continued across all three patient segments in the fourth quarter, with 34% of patients being new to oxybates and 38% switching from first-generation oxybates.
The company expects the net product revenue for 2025 in the range of $240 million to $260 million, representing a 50% increase at the midpoint of guidance from 2024 and a positive cash flow of $20 million – $40 million.
Divis added that moving into 2025, the company is refining its strategy to increase LUMRYZ&#8217;s demand and aiming to drive uptake across all narcolepsy patient segments. &#8220;We&#8217;re well-positioned to lead in the sleep space and transform care for patients with sleep disorders.&#8221; he said.
Price Action: Avadel shares have fallen by 32.72% over the last six months, underperforming the Nasdaq Biotechnology Index, which fell by 5.07% in the same period. Furthermore, the exchange-traded fund tracking the index, iShares Biotechnology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NASDAQ">IBB</a>) fell 2.9% over the last six months.
According to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data, AVDL has a consensus price target of $20.9 per share, with a &#8216;buy&#8217; rating based on the ratings of 10 <a href="https://www.benzinga.com/quote/SERV/analyst-ratings">analysts</a>. The highest price target out of all the analysts tracked by Benzinga is $30 issued by Oppenheimer as of Oct. 31, 2024. The lowest target price is $11 per share issued by Jefferies on Nov. 30, 2024.
The average price target between HC Wainwright &amp; Co., Needham, and Needham implies an 189.31% upside for AVDL.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/SERV/analyst-ratings"><img loading="lazy" decoding="async" width="946" height="355" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09010640/AVDL-ANR.png" alt="" class="wp-image-725276" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09010640/AVDL-ANR.png 946w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09010640/AVDL-ANR-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09010640/AVDL-ANR-768x288.png 768w" sizes="(max-width: 946px) 100vw, 946px" /></a></figure>
Photo Courtesy: Pixabay.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42867184/yield-curve-normalization-cheap-valuation-eps-growth-to-boost-banks-in-2025-truist-initiates-coverage-on-these-14-regional-names">Yield Curve Normalization, Cheap Valuation, EPS Growth To Boost Banks In 2025: Truist Initiates Coverage On These 14 Regional Names</a></li>
</ul>

Earnings Misses

Broad U.S. Equity ETFs

Analyst Ratings

ETFs

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From  Narcolepsy Drug LUMRYZ

Burak brings over 27 years of extensive international experience within the finance sector. Burak started his career with Xerox where he held a number of key financial positions in the USA and the UK in addition to serving as the General Manager of Xerox Turkey. More recently Burak has held the position of Chief Financial Officer within the global Digital Transformation, IT Solutions &amp; Cybersecurity space

VEON

VEON Appoints Burak Ozer As CFO, Effective January 9, 2025

Macro Economic Events

Econ #s

Economics

Germany Trade Balance For November 19.7B Vs. 14.7B	Est.; 13.4B Prior

Germany Industrial Production (MoM) For November 1.5% Vs. 0.5% Est.; -0.4% (Revised) Prior

Company Strengthens Long-term Strategy With Agile Adaptability in Rapidly Changing Business Environments

LGEJY

Reported Earlier, LG Electronics CEO William Cho Reveals 2025 Strategy To Build Structural Competitiveness And Drive Qualitative Growth

A major BlackRock Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) fund is confronting a loss exceeding $600 million tied to its investment in the insurance outsourcing firm, Alacrity. This development emerges amid the company&#8217;s ongoing debt challenges.
What Happened: A consortium of private credit funds, including&nbsp;Antares Capital,&nbsp;Blue Owl Capital,&nbsp;KKR, and&nbsp;Goldman Sachs Asset Management, has&nbsp;agreed to take control of&nbsp;Alacrity. BlackRock had acquired a controlling interest in Alacrity&nbsp;in February 2023 through its&nbsp;$4.3 billion&nbsp;Long Term Private Capital strategy, purchasing it from private equity firm&nbsp;Kohlberg &amp; Co., Financial Times <a href="https://www.ft.com/content/26148be7-38de-40ea-8432-84bf947c1ba3">reported</a> on Thursday.
BlackRock&#8217;s equity investment in Alacrity, valued at over $600 million, will be eliminated&nbsp;as part of the restructuring,&nbsp;as reported by sources familiar with the situation. At the time of BlackRock&#8217;s investment, Alacrity had approximately $1 billion in senior debt and $500 million in junior debt, the latter provided by Goldman's asset management division.
The restructuring plan involves converting these debts into a new $450 million term loan and $250 million in preferred equity. Senior lenders will acquire 90% ownership of the company post-restructuring, while Goldman Sachs Asset Management will hold the remaining 10%.
BlackRock has yet to respond to<a href="https://pro.benzinga.com"> Benzinga</a>&#8216;s queries.
Why It Matters: The timing of this financial loss is critical for BlackRock as it prepares to release its fourth-quarter earnings on Jan. 15. Analysts anticipate the company will report earnings of $11.38 per share, a significant increase from $9.66 per share in the previous year. Revenue is projected to reach $5.63 billion, up from $4.63 billion a year earlier. This restructuring loss could impact investor sentiment and the company&#8217;s financial outlook.
Moreover, BlackRock&#8217;s recent definitive agreement to acquire&nbsp;<a href="https://www.benzinga.com/markets/25/01/42888338/blackrock-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">HPS Investment Partners</a>&nbsp;for approximately $12 billion underscores its strategic moves to expand its investment capabilities. The Alacrity restructuring, however, highlights the risks inherent in such large-scale investments and the challenges of managing debt-laden assets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/insights/options/25/01/42882658/honeywell-intl-options-trading-a-deep-dive-into-market-sentiment">Honeywell Intl Options Trading: A Deep Dive into Market Sentiment</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo by rafapress on Shutterstock

BlackRock Reportedly Faces $600 Million Loss In Alacrity Restructuring Ahead Of Earnings Report

Do Kwon, co-founder of disgraced Terraform Labs, will face trial in a year&#8217;s time for his alleged role in the $40 billion criminal fraud case involving the collapse of Terra Classic (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">LUNC</a>) and sister stablecoin TerraUSD (USTC), according to a report on Wednesday.
What Happened: U.S. District Judge Paul Engelmayer set a trial date for Jan. 26, 2026, in New York, <a href="https://www.bloomberg.com/news/articles/2025-01-08/terraform-s-do-kwon-to-face-2026-trial-in-ny-on-us-fraud-charges">expected </a>to last for four to eight weeks, Bloomberg reported.
Kwon has been <a href="https://www.benzinga.com/news/global/25/01/42773042/terra-lunas-do-kwon-to-face-criminal-fraud-charges-in-us">accused of various counts of commodities fraud</a>, conspiracy, securities fraud, and wire fraud in connection with the collapse of LUNC and stablecoin TerraUSD in 2022, which caused an estimated $40 billion loss.
The drop had far-reaching consequences, undermining investor confidence and resulting in prolonged months of lower valuations, also known as a bear market.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/01/42835979/ethereum-co-founder-vitalik-buterin-offloads-nearly-a-million-in-memecoins-to-benefit-charitiesdogecoins-sister-coin-neiro-plunges-3-after-sale">Ethereum Co-Founder Vitalik Buterin Offloads Nearly A Million In Memecoins To Benefit Charities — Dogecoin&#8217;s Sister Coin NEIRO Plunges 3% After Sale</a>
Kwon was extradited from Montenegro to face these charges in a U.S. court. He pleaded not guilty to these charges.
Do Kwon&#8217;s extradition <a href="https://www.benzinga.com/25/01/42758091/terra-classic-token-rallies-as-terraform-labs-do-kwon-extradited-to-the-us-from-montenegro">ended a legal tug-of-war</a> between the U.S. and South Korea, his native country, over competing extradition requests.
Price Action: At the time of writing, LUNC was exchanging hands at $0.0001036, down 2.77% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>. The coin has lost nearly 20% of its value in the last month.
Photo Courtesy: July Ko On Shutterstock.com
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/42836019/odds-of-trump-buying-greenland-hit-21-on-betting-platform-kalshi-amid-reports-of-donald-trump-jrs-visit-to-arctic-region">Trump&#8217;s Greenland Gambit: Kalshi Bettors See 21% Chance He&#8217;ll Seal The Deal Before This Date</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$LUNC

Terra Classic Sinks As Terraform Founder Do Kwon Set To Stand Trial In 2026 For Alleged $40 Billion Fraud

Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg's accusation of censorship has been firmly denied by the European Commission.
What Happened: On Wednesday, the European Commission dismissed claims by Meta that EU data laws censor social media, reported Reuters.
The Commission stated that their regulations only mandate the removal of illegal content. &#8220;We absolutely refute any claims of censorship,&#8221; said a Commission spokesperson.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/42837406/amid-nvidias-ces-2025-buzz-investors-overlooked-apple-supplier-foxconns-strong-q4-says-jim-cramer">Amid Nvidia's CES 2025 Buzz, Investors Overlooked Apple Supplier Foxconn's Strong Q4, Says Jim Cramer</a>
Zuckerberg had criticized European laws, stating they hinder innovation by institutionalizing censorship. In response, the Commission said that the Digital Services Act does not compel platforms to remove lawful content but targets harmful material.
Meta has decided to <a href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression">eliminate fact-checkers</a> for its platforms in the U.S., opting for a &#8220;community notes&#8221; system similar to that used by Elon Musk's X.
The European Commission noted that for such a system to operate in the EU, platforms must conduct risk assessments and submit them to the EU executive.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: The tension between Meta Platforms and the European Union is not new. In November 2024, the European Commission imposed an <a href="https://www.benzinga.com/government/regulations/24/11/41981957/meta-hit-with-841-million-eu-fine-over-antitrust-violations-tied-to-facebook-marketplace">$841 million fine</a> on Meta for antitrust violations related to Facebook Marketplace.
Later in December, Meta faced another setback when the Irish Data Protection Commission fined the company <a href="https://www.benzinga.com/24/12/42537434/meta-fined-264-million-over-2018-facebook-data-breach-in-europe">$264 million over a 2018 data breach</a>.&nbsp;
Price Action: Meta's stock closed Wednesday's trading session down 1.16%, finishing at $610.72. In after-hours trading, the shares dipped an additional 0.34%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Photo Courtesy: Flickr.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42513402/apples-2025-bull-case-can-it-deliver-without-riding-the-ai-wave?itm_source=parsely-api">Apple&#8217;s 2025 Bull Case: Can It Deliver Without Riding The AI Wave?</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

Social Media

Media

Mark Zuckerberg Accuses EU Of Censorship, Spokesperson Pushes Back On Meta's Allegations: 'We Absolutely Refute Any Claims'

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) inventory in the U.S. now shows non-foundation series Cybertrucks listed together with the more premium foundation series of the vehicle.
What Happened: At the start of the week, Tesla had only foundation series Cybertrucks listed on its inventory. 
The foundation series refers to a limited and pricier edition of the Cybertruck with laser-etched foundation series badges and premium accessories.
Tesla made only the foundation series Cybertrucks for the first few months of deliveries. In October, Tesla started selling the regular version of Cybertruck priced about $20,000 lower than the foundation series.
Tesla&#8217;s inventory now shows multiple non-foundation series Cybertrucks, priced lower than the foundation series offerings. While the non-foundation series all-wheel drive variant of the Cybertruck has a starting price of $79,990, the non-foundation series Cyberbeast variant of the truck starts at $99,990. 
Why It Matters: Benzinga first noted the&nbsp;<a href="https://www.benzinga.com/tech/24/12/42524912/teslas-99k-foundation-series-cybertrucks-still-available-a-sign-of-possible-demand-hurdles" target="_blank" rel="noreferrer noopener">foundation series Cybertrucks in Tesla's inventory</a>&nbsp;in mid-December. Tesla has, since then, added offers&nbsp;<a href="https://www.benzinga.com/tech/24/12/42712707/tesla-offers-free-lifetime-supercharging-with-foundation-series-cybertruck-as-it-looks-to-clear-inventory" target="_blank" rel="noreferrer noopener">including free supercharging</a>&nbsp;on the vehicle if the order is placed on or after Dec. 27. The offer, it then said, will only be available for a limited time.
However, a week later, there are still foundation-series Cybertrucks left in the inventory and the company is continuing to offer free supercharging during the period of initial ownership, hinting that potential customers might be unwilling to<a href="https://www.benzinga.com/tech/24/11/41873767/cybertruck-likely-wont-be-profitable-in-q4-says-tesla-researcher" target="_blank" rel="noreferrer noopener">&nbsp;pay a premium for the stainless steel truck.</a>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42840097/nhtsa-opens-probe-into-26-million-tesla-vehicles-after-complaint-of-crash-involving-actually-smart-summon-feature" target="_blank" rel="noreferrer noopener">NHTSA Opens Probe Into 2.6 Million Tesla Vehicles After Complaint Of Crashes Linked To Actually Smart Summon Feature</a></li>
</ul>
Photo courtesy: Tesla

TSLA

Tesla's Inventory Now Includes Non-Foundation Series Cybertrucks

<ul>
<li>The VENTANA DP 600 slide scanner, part of Roche's Digital Pathology Dx system, is now cleared by the FDA to aid in clinical diagnosis, enabling pathologists to diagnose patients using digital images. &nbsp;</li>
<li>This 240-slide scanner produces excellent image quality of stained histology slides from patient tissue samples, while providing ease-of-use and workflow flexibility for the pathology lab. &nbsp;</li>
<li>Primary diagnosis in digital pathology helps enhance diagnostic accuracy, consistency, and speed by providing high-resolution images and advanced analysis tools.</li>
</ul>

RHHBF

RHHBY

RHHVF

Roche's Digital Pathology Dx System Expands With FDA Approval Of High-Capacity VENTANA DP 600 Scanner

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
<ul>
<li>Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV</li>
<li>IRAKLIA is the first global phase 3 study to evaluate the SC administration of a cancer treatment via an OBDS</li>
<li>OBDS is an alternative delivery method designed to improve the patient experience and currently available SC administration</li>
</ul>

Sanofi's Sarclisa Subcutaneous Formulation Achieves Co-Primary Endpoints In IRAKLIA Phase 3 Trial For Multiple Myeloma Treatment

The International Longshoremen&#8217;s Association and U.S. Maritime Alliance reached a tentative six-year master contract agreement on Wednesday, averting potential supply chain disruptions at East Coast and Gulf ports ahead of the Jan. 15 deadline.
The deal, which requires ratification from both parties, notably includes compromises on port automation while preserving labor protections. 
Sources familiar with the negotiations <a href="https://www.cnbc.com/2025/01/08/union-dockworkers-port-employers-announce-tentative-labor-deal-at-east-coast-and-gulf-ports.html">told</a> CNBC that while full automation was excluded, USMX members gained the flexibility to implement modernization technologies, with guaranteed ILA positions tied to new equipment deployments.
A technology committee, including ILA President Harold Daggett and other union and port representatives, will oversee future technological implementations. The arrangement aims to enhance port efficiency and capacity while maintaining strong labor relations through 2031.
Both organizations stated in a joint announcement that the agreement &#8220;creates ILA jobs, supports American consumers and businesses, and keeps the American economy the key hub of the global marketplace.&#8221; Specific terms remain undisclosed pending member review and ratification votes, for which dates have not been set.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42890464/softbank-owned-arm-eyes-acquisition-of-oracle-backed-chip-designer-ampere-computing-amid-nvidias-dominance-report">SoftBank-Owned Arm Eyes Acquisition Of Oracle-Backed Chip Designer Ampere Computing Amid Nvidia&#8217;s Dominance: Report</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

East Coast Ports Avoid Disruptions As Union, Maritime Alliance Reach 6-Year Deal On Automation, Labor Protections

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sunrise New Energy&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/epow-stock-quote/">EPOW</a>) stock is up on Monday after the lithium-ion battery maker was <a href="https://www.nasdaq.com/press-release/sunrise-new-energys-lithium-ion-battery-patent-granted-key-funding-guizhou-province">granted new patent funding</a>.



This was granted to its subsidiary Sunrise (Guizhou) New Energy. The patent funding comes from the 2024 Guizhou Provincial Key Projects for Promoting the Utilization of Intellectual Property.



According to Sunrise New Energy, this covers its Patent No. ZL202210400775.2, which is titled &ldquo;Preparation Method of Lithium-Ion Battery Anode Material.&rdquo; It says this patent improves the initial efficiency and power performance of the graphite composite materials used in lithium-ion batteries.



Sunrise New Energy said the following about the patented product.




&ldquo;Due to its stable performance, the patented product holds a significant competitive advantage in the market and has received unanimous praise for its quality. Since the sales of the patented product began in 2022, despite the short period, the product has rapidly gained market traction. To date, the cumulative sales revenue has reached approximately $100 million.&rdquo;




<h2>EPOW Stock Movement on Monday</h2>



With all of this news comes heavy trading of Sunrise New Energy this morning. That has more than 4 million shares changing hands as of this writing. This is well above the company&rsquo;s daily average trading volume of about 35,000 shares.



EPOW stock is up 33.6% as of Monday morning.



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news ready to go on Monday! Among that is what has shares of Agrify&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/agfy-stock-quote/">AGFY</a>) stock up, the biggest pre-market stock movers and more. All of this info is good to go at the links below!



<h2>More Stock Market News for Monday</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-agrify-agfy-stock-up-70-today/">Why Is Agrify (AGFY) Stock Up 70% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-june-24th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Monday</a></li>



<li><a href="https://investorplace.com/2024/06/archer-aviation-achr-stock-pops-on-san-francisco-plans/">Archer Aviation (ACHR) Stock Pops on San Francisco Plans</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-sunrise-new-energy-epow-stock-up-34-today/">Why Is Sunrise New Energy (EPOW) Stock Up 34% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Sunrise New Energy (EPOW) Stock Up 34% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
G1 Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/gthx-stock-quote/">GTHX</a>) stock is falling hard on Monday after the company provided investors with an <a href="https://www.nasdaq.com/press-release/g1-therapeutics-provides-update-phase-3-preserve-2-trial-patients-receiving">update on its Phase 3 clinical trial</a> of trilaciclib as a breast cancer treatment.



G1 Therapeutics notes that this trial failed to meet its primary endpoint. The overall survival rate for those taking its drug prior to chemotherapy was 17.4 months. The overall survival rate for the control arm was 17.8 months.



G1 Therapeutics does note that the occurrence of severe neutropenia was lower in those taking trilaciclib ahead of chemotherapy. This came in at 8% of patients as compared to 29% in the control group.



G1 Therapeutics CEO Jack Bailey said the following about the Phase 3 clinical trial results.




&ldquo;The unexpected results from PRESERVE 2 underscore the challenge of developing new therapies for triple negative breast cancer. We are disappointed that this trial did not deliver the benefit that we anticipated to people living with TNBC.&rdquo;




<h2>What&rsquo;s Next for GTHX Stock?</h2>



G1 Therapeutics says it will start to wind down operations connected to its Phase 3 clinical trial of trilaciclib. This will see the company reduce its headcount and provide it with a cash runway into the second half of 2025.



G1 Therapeutics also provides guidance for fiscal 2024. This has it expecting revenue from COSELA to range from $60 million&nbsp;and&nbsp;$70 million. Wall Street is looking for 2024 revenue to come in at $72.26 million.



GTHX stock is down 55.7% as of Monday morning. The stock was also down 20.3% year-to-date when markets closed on Friday.



Investors will want to keep reading for more of the most recent stock market stories today!



We have all of the hottest stock market news available on Monday! That includes everything happening with shares of DermTech&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>), Sunrise New Energy&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/epow-stock-quote/">EPOW</a>) and Agrify&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/agfy-stock-quote/">AGFY</a>) stock today. All of this news is ready at the following links!



<h2>More Stock Market News for Monday</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-dermtech-dmtk-stock-down-26-today/">Why Is DermTech (DMTK) Stock Down 26% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-sunrise-new-energy-epow-stock-up-34-today/">Why Is Sunrise New Energy (EPOW) Stock Up 34% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-agrify-agfy-stock-up-70-today/">Why Is Agrify (AGFY) Stock Up 70% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-g1-therapeutics-gthx-stock-down-56-today/">Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ginkgo Bioworks (NYSE:<a href="https://investorplace.com/stock-quotes/dna-stock-quote/">DNA</a>) layoffs are coming for 158 of the company&rsquo;s employees and more are on the way.



Ginkgo Bioworks has revealed that it&rsquo;s going to be cutting 158 jobs as part of its effort to reduce its labor costs by 25%. On top of that, the company says that an unknown number of jobs will be cut next week.



These are the layoffs announced by Ginkgo Bioworks back in May. The headcount reductions follow a lackluster earnings report a few weeks ago. That also saw the company lower its outlook for the year.



Ginkgo Bioworks co-founder and CEO Jason Kelly said the following about the layoffs to The Boston Globe.




&ldquo;These are amazing employees who are being let go as part of changes we are making to our technology platform at Ginkgo and a near term focus on reaching breakeven. We are sad to see them go.&rdquo;




<h2>Ginkgo Bioworks Layoffs: What&rsquo;s Next</h2>



DNA continues to struggle after its earnings report. On top of the layoffs, the company is also in danger of being delisted from the New York Stock Exchange. It&rsquo;s shares trading below $1 each puts it in danger of delisting.



With the layoffs news comes a 6.3% drop for DNA stock today. That builds on its 76.2% drop since the start of the year.



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news available on Monday! Among that is what has shares of G1 Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/gthx-stock-quote/">GTHX</a>), DermTech&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) and Sunrise New Energy&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/epow-stock-quote/">EPOW</a>) stock on the move today. All of that news is ready at the following links!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-g1-therapeutics-gthx-stock-down-56-today/">Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-dermtech-dmtk-stock-down-26-today/">Why Is DermTech (DMTK) Stock Down 26% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-sunrise-new-energy-epow-stock-up-34-today/">Why Is Sunrise New Energy (EPOW) Stock Up 34% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/ginkgo-bioworks-layoffs-2024-what-to-know-about-the-latest-dna-job-cuts/">Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts

Sunrise New Energy secures $13.76M low-interest loan from China Construction Bank

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Wednesday with our breakdown of all the biggest news affecting shares this morning.



Moving stocks this morning are merger agreements, eaernings reports, late filings notices and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Vivopower (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/">VVPR</a>) stock is rocketing more than 75% as its Tembo subsidiary <a href="https://www.nasdaq.com/press-release/vivopowers-tembo-confirms-heads-agreement-exclusivity-extension-us-838m-merger-ccts">prepares for a merger</a>.</li>



<li>Zoomcar (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcar-stock-quote/">ZCAR</a>) shares are soaring over 33% with the <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318428597&amp;type=PDF&amp;symbol=ZCAR&amp;cdn=815824f42d62c01bbe441848d3eae09a&amp;companyName=Zoomcar+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-07-01">departure of its CEO</a> and a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318432468&amp;type=PDF&amp;symbol=ZCAR&amp;cdn=dc00ab75a334038308b226d996648882&amp;companyName=Zoomcar+Holdings+Inc.&amp;formType=NT+10-K&amp;formDescription=Notification+of+inability+to+timely+file+Form+10-K+405%2C+10-K%2C+10-KSB+405%2C+10-KSB%2C+10-KT%2C+or+10-KT405&amp;dateFiled=2024-07-02">late filing notice</a>.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) stock is surging more than 27% alongside heavy pre-market trading.</li>



<li>Caravelle (NASDAQ:<a href="https://investorplace.com/stock-quotes/caco-stock-quote/">CACO</a>) shares are gaining over 24% without any clear news this morning.</li>



<li>CureVac (NASDAQ:<a href="https://investorplace.com/stock-quotes/cvac-stock-quote/">CVAC</a>) stock is increasing more than 23% on <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-buys-full-rights-make-covid-influenza-vaccines-curevac-2024-07-03/">news of a vaccine sale</a>.</li>



<li>DouYu (NASDAQ:<a href="https://investorplace.com/stock-quotes/doyu-stock-quote/">DOYU</a>) shares are rising over 22% after announcing a <a href="https://www.nasdaq.com/press-release/douyu-international-holdings-limited-announces-special-cash-dividend-2024-07-03">special cash dividend</a>.</li>



<li>MSP Recovery (NASDAQ:<a href="https://investorplace.com/stock-quotes/lifw-stock-quote/">LIFW</a>) stock is heading more than 20% higher despite a lack of news this morning.</li>



<li>Koss (NASDAQ:<a href="https://investorplace.com/stock-quotes/koss-stock-quote/">KOSS</a>) shares are climbing over 19% without any obvious news to report.</li>



<li>Scilex (NASDAQ:<a href="https://investorplace.com/stock-quotes/sclx-stock-quote/">SCLX</a>) stock is jumping more than 18% as subsidiary Semnur Pharmaceuticals <a href="https://www.globenewswire.com/news-release/2024/07/02/2907841/0/en/Semnur-Pharmaceuticals-Inc-a-Wholly-Owned-Subsidiary-of-Scilex-Holding-Company-and-Denali-Capital-Acquisition-Corp-Nasdaq-DECA-Enter-into-a-Letter-of-Intent-for-a-Proposed-Business.html">enters a merger agreement</a>.</li>



<li>U Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucar-stock-quote/">UCAR</a>) shares are up close to 18% after <a href="https://www.nasdaq.com/press-release/u-power-expands-global-footprint-strategic-move-thai-market-2024-07-03">announcing an expansion into Thailand</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Shapeways (NASDAQ:<a href="https://investorplace.com/stock-quotes/shpw-stock-quote/">SHPW</a>) stock is plummeting over 39% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318434959&amp;type=PDF&amp;symbol=SHPW&amp;cdn=ad248035b57b9d6b5efbd20955a6955d&amp;companyName=Shapeways+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-07-03">filing for Chapter 7 bankruptcy</a>.</li>



<li>First Foundation (NYSE:<a href="https://investorplace.com/stock-quotes/ffwm-stock-quote/">FFWM</a>) shares are diving more than 27% with the release of its <a href="https://www.nasdaq.com/press-release/first-foundation-inc-announces-second-quarter-2024-earnings-conference-call-details">Q2 earnings report</a>.</li>



<li>Upexi (NASDAQ:<a href="https://investorplace.com/stock-quotes/upxi-stock-quote/">UPXI</a>) stock is taking an over 13% beating <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318432555&amp;type=PDF&amp;symbol=UPXI&amp;cdn=9b1bbc06760a8be879bdd983cb8a3296&amp;companyName=Upexi+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-07-02">with a late filing</a>.</li>



<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) shares are tumbling more than 13% after <a href="https://www.nasdaq.com/press-release/eshallgo-inc-announces-pricing-initial-public-offering-2024-07-01">pricing a public offering</a>.</li>



<li>Universe Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/upc-stock-quote/">UPC</a>) stock is sliding over 12% this morning.</li>



<li>Noah (NYSE:<a href="https://investorplace.com/stock-quotes/noah-stock-quote/">NOAH</a>) shares are falling more than 10% without any apparent news today.</li>



<li>Sunrise New Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/epow-stock-quote/">EPOW</a>) stock is dropping over 9% this morning.</li>



<li>Ocean Power Technologies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/optt-stock-quote/">OPTT</a>) shares are decreasing more than 9% <a href="https://investorplace.com/2024/07/why-is-ocean-power-optt-stock-up-80-today/">after a rally yesterday</a>.</li>



<li>Forge Global (NYSE:<a href="https://investorplace.com/stock-quotes/frge-stock-quote/">FRGE</a>) stock is slipping nearly 9% on Wednesday.</li>



<li>Golden Heaven (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdhg-stock-quote/">GDHG</a>) shares close out our pre-market stock movers down over 8% after a Tuesday rally.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-3rd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Sunrise New Energy Co (EPOW) has released an update. Sunrise New Energy Co., a company known for its innovation in the energy sector, has announced...

Sunrise New Energy Calls Meeting for Share Consolidation

Sunrise New Energy regains compliance with Nasdaq's listing rule

Sunrise New Energy Co (EPOW) has released an update. Sunrise New Energy Co., Ltd. shareholders approved major corporate actions during their extrao...

Sunrise New Energy Shareholders Approve Key Resolutions

Sunrise New Energy (EPOW) announced robust sales growth, highlighting its expanding influence in the electric vehicle and energy storage sectors. I...

Sunrise New Energy achieves sales volume of 3,419 tons in October

An update from Sunrise New Energy Co ( ($EPOW) ) is now available. Sunrise New Energy Co. has reported a significant increase in its total assets a...

Sunrise New Energy Co. Sees Significant Asset Growth Amid Rising Liabilities

AGFY

CACO

CVAC

DMTK

DOYU

EHGO

FFWM

FRGE

GDHG

GTHX

KOSS

LIFW

MAXN

NOAH

OPTT

SCLX

SHPW

UCAR

UPXI

VVPR

ZCAR

Press Releases

Sunrise Achieves Significant Milestone with Delivery of 5,800 Tons to HiTHIUM, a Global Leading Energy Storage Battery Manufacturer

Sunrise Secures New Key Client with Significant Order

Sunrise New Energy Secures $13.76 Million Low-Interest Loan from CCB

Sunrise Announces Successful Development of New Generation Porous Silicon-Carbon Material for Solid-State Batteries

Sunrise New Energy Launches High-Energy Density and High-Rate Silicon-Carbon Anode Products for Solid-State Batteries

Sunrise Secures Additional $13.75 Million Low-Interest Loan from CCB, Bolstering Liquidity for Order Fulfillment

Sunrise Records 132% Surge in First-Half Sales Volume, Featured in Guizhou TV Report as a Leading Anode Materials Manufacturer

Sunrise Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Sunrise Secures $1.04 Million in Funding for Innovative Silicon-Carbon Anode Project

Sunrise Sunrise Reports Strong Sales Growth Driven by Leading EV and Energy Storage Customers

Aeries Technology, Inc. - Class A Ordinary Share

Aeries Technology

BlackSky Technology Inc. Class A Common Stock

BlackSky Technology

Earlyworks Co., Ltd. - American Depositary Shares

Earlyworks Co

Falcon's Beyond Global, Inc. - Class A Common Stock

Falcons Beyond Global

Franklin Covey

Forrester Res

Graphex Group Limited American Depositary Shares, each American Depositary Share representing 20 Ordinary Shares

Graphex Gr

Lichen China Limited - Class A Ordinary Shares

Lichen China

MISTRAS Group

FiscalNote Holdings, Inc. Class A common stock

FiscalNote Holdings

RCM Technologies

Resources Connection, Inc. - Common Stock

Resources Connection

SOS Limited American Depositary Shares, one hundred and fifty (150) Class A Ordinary Shares

Comments

Sunrise New Energy

Noticias

Últimas noticias sobre Sunrise New Energy (NASDAQ:EPOW) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL